Aligos Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALGS Nasdaq 2836 www.aligos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aligos Therapeutics, Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 12th, 2025 6:00 am
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Dec 11th, 2025 6:00 am
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 - Nov 10th, 2025 6:00 am
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Nov 6th, 2025 6:30 am
Aligos Therapeutics to Present at Upcoming Investor Conferences - Nov 4th, 2025 6:30 am
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 - Oct 30th, 2025 6:30 am
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 - Oct 16th, 2025 6:30 am
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference - Oct 14th, 2025 6:30 am
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 - Oct 7th, 2025 6:30 am
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect? - Sep 8th, 2025 3:04 pm
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - Sep 3rd, 2025 2:05 pm
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 2:05 pm
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia - Sep 1st, 2025 10:30 am
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study - Aug 21st, 2025 9:13 am
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - Aug 20th, 2025 6:30 am
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know - Aug 19th, 2025 7:55 am
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Aug 14th, 2025 9:11 am
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment - Aug 14th, 2025 3:51 am
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection - Aug 13th, 2025 6:30 am
Aligos Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Aug 9th, 2025 6:29 am